Abstract
Introduction
It remains controversial whether polypoidal choroidal vasculopathy (PCV) represents a subtype of neovascular age-related macular degeneration (nAMD) or is a distinct disease entity. This study aimed to compare and analyze systemic and serum risk factors for nAMD and PCV in an aging Chinese population.
Methods
A retrospective study was performed on 108 patients with nAMD, 131 patients with PCV, and 219 control subjects. Serum levels of total cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL), high-density lipoprotein (HDL), apolipoprotein A1 (APOA1), apolipoprotein B (APOB), complement 3 (C3), and complement 4 (C4) together with data on systemic risk factors, including hyperlipidemia, hypertension, diabetes mellitus (DM), coronary artery disease (CAD), and asthma, were collected. Chi-square tests, independent-samples t tests, and binary logistic regression analyses were performed to evaluate the associations of risk factors with nAMD and PCV.
Results
Patients with PCV and those with nAMD were likely to have hyperlipidemia (P < 0.001). CAD (P = 0.020) and hypertension (P = 0.006) correlated significantly with nAMD and PCV, respectively. Although no association of age and asthma with PCV or nAMD was found (P > 0.05), DM was associated with PCV development (OR = 0.535, P = 0.044). Regarding serum risk factors, HDL, LDL, TG, APOB, and C3 were significantly associated with nAMD (OR < 0.001, P < 0.001; OR = 0.028, P < 0.001; OR = 0.175, P < 0.001; OR = 0.922, P = 0.022; OR < 0.001, P < 0.001) and PCV (OR = 0.001, P = 0.001; OR = 0.097, P = 0.003; OR = 0.410, P = 0.037; OR = 0.895, P = 0.001; OR = 0.001, P < 0.001). Compared with nAMD, higher levels of HDL (P = 0.003) and LDL (P = 0.016) and lower levels of TG (P = 0.039) were found in patients with PCV, but the association of systemic risk factors between the two diseases was not significant (P > 0.05).
Conclusion
Our findings indicate that hyperlipidemia is significantly associated with both nAMD and PCV. Serum lipid and complement levels have an effect on the pathogenesis of nAMD and PCV, and consideration of the differences between systemic and serum risk factors should be taken into account in clinical management.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Why carry out this study? |
At present, it is not clear whether polypoidal choroidal vasculopathy (PCV) is a subtype of neovascular age-related macular degeneration (nAMD) or a distinct disease within the pachychoroid disease spectrum. |
We aimed to evaluate systemic and serum risk factors in PCV and nAMD to comprehensively analyze the difference in pathogenesis between these two diseases. |
What was learned from this study? |
Compared to the control group, patients with nAMD and PCV were more likely to have coronary artery disease and hypertension, respectively, and hyperlipidemia was significantly associated with both nAMD and PCV. |
The aberrant changes in levels of serum lipids (high-density lipoprotein, low-density lipoprotein, and total cholesterol) in PCV patients, combined with the lower level of complement 3, indicate that the molecular mechanism underlying PCV development differs from that of nAMD. |
Introduction
Neovascular age-related macular degeneration (nAMD), which is characterized by the development of choroidal neovascularization (CNV), is more prevalent than geographic atrophy in China and is a common cause of blindness [1, 2]; First reported in the 1990s, polypoidal choroidal vasculopathy (PCV) is described as abnormal dilations of terminals of branching vascular networks, which are often best demonstrated by indocyanine green angiography (ICGA), and it is considered to be a subtype of AMD [3,4,5]. Although PCV appears to differ from nAMD based on clinical findings, epidemiological features, and treatments, whether PCV should be defined as a distinct disease entity remains controversial [6, 7].
To date, some studies have focused on risk factors for nAMD or PCV in the Asian population. For example, in a Chinese cohort, patients who smoked were more likely to present ocular features associated with nAMD and PCV [8]. This finding was similar to that of Masato et al. [9], who reported that patients in Japan with nAMD and PCV were frequently smokers. However, the prevalence of other factors, including sex, hypertension, coronary artery disease (CAD), hyperlipidemia, diabetes mellitus (DM), and asthma, reportedly differs between nAMD and PCV [10,11,12].
Cholesterol is an important constituent of drusen, and serum lipids are considered to be a risk factor for AMD development [13,14,15]. In patients who experience symptoms for longer than 3 months, leakage from active aneurysmal elements results in considerable lipid depositions in polypoidal vascular abnormalities [16]. Thus far, there are a limited number of studies analyzing lipid levels in PCV development, and epidemiological findings of the association of serum lipid levels with PCV are inconsistent [17,18,19]. Therefore, it is necessary to obtain more evidence to elucidate the role of lipid/lipoprotein concentrations in the development of AMD or PCV. Although it is known that complement-mediated inflammation plays an important role and excessive complement system activation leads to inflammation and tissue impairment in AMD [20,21,22], few studies have described serum concentrations of complements in patients with PCV.
The results of our previous study suggest significant associations between hyperlipidemia and PCV [23]. Thus, we performed a comprehensive analysis to compare systemic risk factors and serum levels, including high-density lipoprotein (HDL), low-density lipoprotein (LDL), total cholesterol (TC), triglycerides (TG), apolipoprotein A1 (APOA1), apolipoprotein B (APOB), complement 3 (C3), and complement 4 (C4), in cases and controls to further evaluate the characteristics of nAMD and PCV and whether they are the same ocular disease.
Methods
Subjects
A total of 458 unrelated Chinese participants were enrolled in this case–control cohort from January 2018 to December 2020, and they comprised 108 patients with nAMD, 131 patients with PCV, and 219 controls. The study subjects were recruited in a consecutive manner from the Department of Ophthalmology of Peking University People’s Hospital, and they signed informed consent before participating in this research. The procedure was approved by the Ethical Committee of Peking University People’s Hospital and was performed in accordance with the tenets of the Declaration of Helsinki. All participants underwent a standard ophthalmic examination, including assessment of visual acuity, slit-lamp biomicroscopy, and dilated fundus examinations, which was performed by two ophthalmic specialists to avoid potential diagnostic bias. All patients with nAMD and PCV underwent fluorescein fundus angiography (FFA), optical coherence tomography (OCT), and ICGA with an HRA2 device (Heidelberg Engineering, Heidelberg, Germany).
The International Classification System for Age-Related Maculopathy (ARM) was applied for nAMD diagnosis [24]. Patients were defined as having typical CNV, serous retinal detachment, subretinal hemorrhage, serous/hemorrhagic retinal pigment epithelial detachment, and fibrosis, with no evidence of polypoidal lesions. The diagnosis of PCV was based on ICGA results that indicated a branching vascular network terminating in polypoidal swelling. Cases with any other macular abnormalities, such as pathological myopia, presumed ocular histoplasmosis, idiopathic CNV, or other secondary CNV, were excluded. All diagnoses and evaluations of nAMD or PCV were performed by two retina specialists, and a third specialist was consulted in cases of discrepancy. Control participants were selected if they met the following criteria: (1) age ≥ 50 years, and (2) fundus examinations revealed normal findings without any signs of PCV, nAMD, or other vitreous/retinal/choroidal pathological alterations. Control subjects with severe cataracts or other remarkable abnormalities in the anterior segment of the eyes were excluded. Data on age, sex, hypertension, hyperlipidemia, CAD, DM, and asthma were obtained through a questionnaire and interview.
Serum Analysis
Fasting serum samples were collected on the same day (January 2018 to December 2020) as the ophthalmic examinations and analyzed for HDL, LDL, TC, TG APOA1, APOB, C3, and C4 in the clinical laboratory at Peking University People’s Hospital. The authors have a terminal system to check the results of blood examinations for participants.
Statistical Analysis
All statistical analyses were performed using SPSS software (version 16; SPSS Science, Chicago, IL). Comparisons of sex and systemic risk factors (hypertension, hyperlipidemia, CAD, DM, and asthma) between the nAMD, PCV, and control groups were analyzed by chi-square tests. Data on age and serum lipid or complement levels are expressed as the mean ± standard deviation (SD), differences between groups were assessed using independent-samples t tests. We analyzed associations between the development of nAMD or PCV and systemic or serum risk factors using a binary logistic regression model to estimate odds ratios (ORs) with 95% confidence intervals (CIs). P < 0.05 was considered statistically significant.
Results
Of the participants, 131 were PCV patients (mean age: 67.67 ± 8.97 years), 108 were nAMD patients (mean age: 69.81 ± 10.02 years), and 219 were controls (mean age: 67.88 ± 9.02 years). The demographic data and prevalence of systemic diseases of the participants are shown in Table 1. Patients with nAMD tended to have CAD (P = 0.020) and hyperlipidemia (P < 0.001); patients with PCV were more likely to have hypertension (P = 0.006) and hyperlipidemia (P < 0.001). No association of DM or asthma with nAMD or PCV was found (P > 0.05).
Table 2 shows the associations of nAMD and PCV with systemic risk factors. In logistic analysis, hyperlipidemia was significantly associated with nAMD (OR = 0.437, P = 0.002; OR = 4.353, P < 0.001), PCV (OR = 0.409, P < 0.001; OR = 4.464, P < 0.001), and nAMD + PCV (OR = 0.449, P < 0.001; OR = 4.217, P < 0.001). DM (OR = 0.535, P = 0.044) was significantly associated with PCV. Other systemic risk factors were not statistically significant (P > 0.05).
The serum levels of lipids and complements in the cases and controls are presented in Table 3. In univariate analysis, patients with nAMD and those with PCV had significantly lower levels of HDL (P < 0.001; P < 0.001), APOA1 (P < 0.001; P < 0.001), APOB (P = 0.032; P = 0.001), and C3 (P < 0.001; P < 0.001) than controls. With regard to LDL, its level was significantly associated with nAMD (P < 0.001).
Furthermore, in logistic analysis (Table 4), levels of HDL, LDL, TG, APOB, and C3 remained associated with nAMD (OR < 0.001, P < 0.001; OR = 0.028, P < 0.001; OR = 0.175, P < 0.001; OR = 0.922, P = 0.022; OR < 0.001, P < 0.001), PCV (OR = 0.001, P = 0.001; OR = 0.097, P = 0.003; OR = 0.410, P = 0.037; OR = 0.895, P = 0.001; OR = 0.001, P < 0.001), and nAMD + PCV (OR = 0.000, P < 0.001; OR = 0.052, P < 0.001; OR = 0.304, P < 0.001; OR = 0.880, P < 0.001; OR = 0.001, P < 0.001).
As illustrated in Table 5 and Table 6, we also analyzed differences in systemic or serum risk factors between nAMD and PCV. Compared with nAMD patients, PCV patients were prone to having higher levels of HDL (P = 0.003) and LDL (P = 0.016) along with lower levels of TG (P = 0.039) in univariate analysis, and levels of HDL and LDL also showed a positive effect in logistic analysis (OR = 3.452, P = 0.022; OR = 4.812, P = 0.004). However, there was no significant difference in systemic risk factors between patients with nAMD and patients with PCV (P > 0.05).
Discussion
In our study, hyperlipidemia showed significant associations with both nAMD and PCV, though other factors, including age, hypertension, CAD, DM and asthma, were not associated with PCV. Although no clear associations of all systemic factors between nAMD and PCV were found, the observed differences in serum lipid levels (HDL, LDL, and TG) suggested that PCV might not be a simple type of AMD and may be a distinct disease entity.
Subretinal hemorrhage (SRH) resulting from vascular terminal dilation in PCV development is a severe complication that causes sudden vision loss, and recurrent SRH is more common in patients with than in those without hypertension [25, 26]. Therefore, hypertension might contribute to the occurrence of polypoidal dilated lesions and sudden vascular rupture. In this study, we found a significant association between hypertension and PCV (P = 0.006). Nevertheless, it is still necessary to perform a study with a larger sample size or experimental research to reveal the potential effect of hypertension on PCV.
To date, the correlation between CAD and AMD is not well defined and rather controversial. In general, the formation of lipid deposition in arterial walls during aging and atherosclerosis is suggested to be similar to the development of esterified lipid-rich deposition or APOB lipid deposition in AMD pathology, resulting in increased choroidal vascular resistance, elevated choriocapillary pressure, decreased choroidal blood flow, and accumulated subretinal deposits. Thomas et al. [27] performed a retrospective study on 3950 patients with AMD and found the existence of an association between CAD and AMD, particularly among older adult patients in the predominantly male population. In addition, the presence of stenotic lesions in the coronary arteries and the severity of stenosis correlate independently with the early stage of AMD, suggesting that patients with CAD are more likely to develop early AMD [28]. These findings are consistent with the significant association between CAD and nAMD (P = 0.020) in our study and strengthen the potential clinical significance of timely diagnosis for AMD in individuals with signs of CAD.
The association between DM and AMD or PCV seen in previous studies is inconsistent with our findings. Cheung et al. [17] did not demonstrate any associations between DM and nAMD or PCV in the Asian population based in Singapore. Conversely, Sakurada et al. [11] found that the percentage of DM in nAMD patients was significantly higher than that in PCV patients, and the severe form of diabetic retinopathy was more prevalent in DM cases with nAMD than in DM cases with PCV. Although the relationship between blood glucose level and PCV remains unclear, the controversial results of some studies might be attributed to different dietary patterns among countries and regions.
Lipid-rich drusen are the hallmark lesions of AMD and accumulate between the retinal pigment epithelium and Bruch’s membrane [29]. Atherosclerosis, as characterized by the generation of atherosclerotic plaques, is a known risk factor for CAD and DM. It is noteworthy that drusen and atherosclerotic plaques also have various components in common, including C3, APOs, and cholesterol [10, 30]. Interestingly, our results showed hyperlipidemia to be a risk factor for both PCV and nAMD (P < 0.001). Therefore, it is necessary to distinguish PCV from nAMD to identify the unique features of the former, and we analyzed levels of serum lipids in patients with nAMD and patients with PCV.
Despite other reports of serum lipid levels associated with AMD, results are conflicting; in particular, there are limited data for PCV. We found that levels of HDL, LDL, TG and APOB were significantly associated with PCV and nAMD (P < 0.05); however, others have shown that differences in serum levels of TG, TC, HDL, and LDL do not differ significantly between patients with PCV or AMD and controls [31,32,33]. Similarly, the level of APOA1, the major protein component of HDL, was not associated with nAMD or PCV in logistic analysis (P > 0.05). In contrast, APOB, the major protein component of LDL, was significantly associated with the two diseases (P < 0.05), which was not consistent with previous findings [15]. As this difference might be due to the ethnicity of the samples, larger multiethnicity studies are needed.
Previous studies have suggested the occurrence of abnormal alterations in complements in AMD pathogenesis [34,35,36]. Our results showed that a lower level of C3 was a risk factor for PCV (P < 0.001), which indicated that complement system activation plays an important role in the development of PCV. It has been reported that depletion of C3 might result from the activation of retinal autoantibodies in AMD patients [37], and further studies are warranted to explore the ocular autoimmune mechanism underlying PCV. Considering the lower levels of lipids and C3, we sought to explore the existence of a relationship between lipid levels and complement activation levels. Comparing PCV with nAMD, we found higher levels of HDL and LDL and lower levels of TG (P < 0.05), which was not completely consistent with previous results, and these risk factors suggested that the pathology of PCV is not similar to that of nAMD [11, 17].
The major limitations of the present study are the relatively small number of cases and that the association of systemic or serum risk factors with nAMD or PCV is poorly understood, so additional studies with larger or more diverse sample sizes will be important to compare risk factors, clinical features, and prognosis between nAMD and PCV.
Conclusion
AMD is a heterogeneous disorder involving the complex interplay between aging, environmental risk factors, and genetic susceptibility [38, 39]. PCV is suggested to belong to the pachychoroid spectrum of diseases, the pathogeneses of which might be associated with vortex veins or running patterns of choroidal vessels [40, 41]. Despite the overlap of clinical or pathophysiological features, alterations in the levels of plasma markers appear to differ between nAMD and PCV [42,43,44,45]. Our findings indicate that the development of nAMD or PCV may correlate with systemic risk factors, especially hyperlipidemia. Serum lipid levels and the complement system are probably involved in both nAMD and PCV. Thus, further studies are required to differentiate between their etiologies, and such findings will be useful for applying appropriate strategies in clinical practice or scientific research in the future.
References
Warwick A, Lotery A. Genetics and genetic testing for age-related macular degeneration. Eye. 2018;32:849–57. https://doi.org/10.1038/eye.2017.245.
Nangia V, Jonas JB, George R, Lingam V, Ellwein L, Cicinelli MV, Das A, Flaxman SR, Keeffe JE, Kempen JH, Leasher J, Limburg H, Naidoo K, Pesudovs K, Resnikoff S, Silvester AJ, Tahhan N, Taylor HR, Wong TY, Bourne RRA. Prevalence and causes of blindness and vision impairment: magnitude, temporal trends and projections in South and Central Asia. Br J Ophthalmol. 2019;103:871–7. https://doi.org/10.1136/bjophthalmol-2018-312292.
Yannuzzi LA, Sorenson J, Spaide RF, Lipson B. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina. 1990;10:1–8.
Lim LS, Cheung CM, Wong TY. Asian age-related macular degeneration: current concepts and gaps in knowledge. Asia Pac J Ophthalmol. 2013;2:32–41. https://doi.org/10.1097/APO.0b013e31827ff5bc.
Lim FP, Wong CW, Loh BK, Chan CM, Yeo I, Lee SY, Mathur R, Wong D, Wong TY, Cheung CM. Prevalence and clinical correlates of focal choroidal excavation in eyes with age-related macular degeneration, polypoidal choroidal vasculopathy and central serous chorioretinopathy. Br J Ophthalmol. 2016;100:918–23. https://doi.org/10.1136/bjophthalmol-2015-307055.
Ciardella AP, Donsoff IM, Yannuzzi LA. Polypoidal choroidal vasculopathy. Ophthalmol Clin N Am. 2002;15:537–54. https://doi.org/10.1016/s0896-1549(02)00053-6.
Yadav S, Parry DG, Beare NAV, Pearce IA. Polypoidal choroidal vasculopathy: a common type of neovascular age-related macular degeneration in Caucasians. Br J Ophthalmol. 2017;101:1377–80. https://doi.org/10.1136/bjophthalmol-2016-310074.
Cackett P, Yeo I, Cheung CM, Vithana EN, Wong D, Tay WT, Tai ES, Aung T, Wong TY. Relationship of smoking and cardiovascular risk factors with polypoidal choroidal vasculopathy and age-related macular degeneration in Chinese persons. Ophthalmology. 2011;118:846–52. https://doi.org/10.1016/j.ophtha.2010.09.026.
Kikuchi M, Nakamura M, Ishikawa K, Suzuki T, Nishihara H, Yamakoshi T, Nishio K, Taki K, Niwa T, Hamajima N, Terasaki H. Elevated C-reactive protein levels in patients with polypoidal choroidal vasculopathy and patients with neovascular age-related macular degeneration. Ophthalmology. 2007;114:1722–7. https://doi.org/10.1016/j.ophtha.2006.12.021.
Pennington KL, DeAngelis MM. Epidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lipid factors. Eye Vis. 2016;3:34. https://doi.org/10.1186/s40662-016-0063-5.
Sakurada Y, Yoneyama S, Imasawa M, Iijima H. Systemic risk factors associated with polypoidal choroidal vasculopathy and neovascular age-related macular degeneration. Retina. 2013;33:841–5. https://doi.org/10.1097/IAE.0b013e31826ffe9d.
Wong CW, Yanagi Y, Lee WK, Ogura Y, Yeo I, Wong TY, Cheung CMG. Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians. Prog Retin Eye Res. 2016;53:107–39. https://doi.org/10.1016/j.preteyeres.2016.04.002.
van Leeuwen R, Klaver CC, Vingerling JR, Hofman A, van Duijn CM, Stricker BH, de Jong PT. Cholesterol and age-related macular degeneration: is there a link? Am J Ophthalmol. 2004;137:750–2. https://doi.org/10.1016/j.ajo.2003.09.015.
Reynolds R, Rosner B, Seddon JM. Serum lipid biomarkers and hepatic lipase gene associations with age-related macular degeneration. Ophthalmology. 2010;117:1989–95. https://doi.org/10.1016/j.ophtha.2010.07.009.
Dashti N, McGwin G, Owsley C, Curcio CA. Plasma apolipoproteins and risk for age related maculopathy. Br J Ophthalmol. 2006;90:1028–33. https://doi.org/10.1136/bjo.2006.093856.
Imamura Y, Engelbert M, Iida T, Freund KB, Yannuzzi LA. Polypoidal choroidal vasculopathy: a review. Surv Ophthalmol. 2010;55:501–15. https://doi.org/10.1016/j.survophthal.2010.03.004.
Cheung CM, Laude A, Yeo I, Tan SP, Fan Q, Mathur R, Lee SY, Chan CM, Tan G, Lim TH, Cheng CY, Wong TY. Systemic, ocular and genetic risk factors for age-related macular degeneration and polypoidal choroidal vasculopathy in Singaporeans. Sci Rep. 2017;7:41386. https://doi.org/10.1038/srep41386.
Gotoh N, Kuroiwa S, Kikuchi T, Arai J, Arai S, Yoshida N, Yoshimura N. Apolipoprotein E polymorphisms in Japanese patients with polypoidal choroidal vasculopathy and exudative age-related macular degeneration. Am J Ophthalmol. 2004;138:567–73. https://doi.org/10.1016/j.ajo.2004.05.025.
Nakata I, Yamashiro K, Kawaguchi T, Gotoh N, Nakanishi H, Akagi-Kurashige Y, Miyake M, Tsujikawa A, Oishi A, Saito M, Iida T, Yamada R, Matsuda F, Yoshimura N. Association between the cholesteryl ester transfer protein gene and polypoidal choroidal vasculopathy. Invest Ophthalmol Vis Sci. 2013;54:6068–73. https://doi.org/10.1167/iovs.13-11605.
Saksens NT, Lechanteur YT, Verbakel SK, Groenewoud JM, Daha MR, Schick T, Fauser S, Boon CJ, Hoyng CB, den Hollander AI. Analysis of risk alleles and complement activation levels in familial and non-familial age-related macular degeneration. PLoS One. 2016;11:e0144367. https://doi.org/10.1371/journal.pone.0144367.
Zipfel PF, Lauer N, Skerka C. The role of complement in AMD. Adv Exp Med Biol. 2010;703:9–24. https://doi.org/10.1007/978-1-4419-5635-4_2.
Despriet DD, Klaver CC, Witteman JC, Bergen AA, Kardys I, de Maat MP, Boekhoorn SS, Vingerling JR, Hofman A, Oostra BA, Uitterlinden AG, Stijnen T, van Duijn CM, de Jong PT. Complement factor H polymorphism, complement activators, and risk of age-related macular degeneration. JAMA. 2006;296:301–9. https://doi.org/10.1001/jama.296.3.301.
Xu N, Xu H, Zhao M, Xu Y, Huang L. Associations of systemic, serum lipid and lipoprotein metabolic pathway gene variations with polypoidal choroidal vasculopathy in China. PLoS One. 2019;14:e0226763. https://doi.org/10.1371/journal.pone.0226763.
Bird AC, Bressler NM, Bressler SB, Chisholm IH, Coscas G, Davis MD, de Jong PT, Klaver CC, Klein BE, Klein R, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol. 1995;39:367–74. https://doi.org/10.1016/s0039-6257(05)80092-x.
Chung YR, Seo EJ, Kim YH, Yang H, Lee K. Hypertension as a risk factor for recurrent subretinal hemorrhage in polypoidal choroidal vasculopathy. Can J Ophthalmol. 2016;51:348–53. https://doi.org/10.1016/j.jcjo.2016.02.012.
Cho JH, Ryoo NK, Cho KH, Park SJ, Park KH, Woo SJ. Incidence rate of massive submacular hemorrhage and its risk factors in polypoidal choroidal vasculopathy. Am J Ophthalmol. 2016;169:79–88. https://doi.org/10.1016/j.ajo.2016.06.014.
Thomas J, Mohammad S, Charnigo R, Baffi J, Abdel-Latif A, Ziada KM. Age-related macular degeneration and coronary artery disease in a VA population. South Med J. 2015;108:502–6. https://doi.org/10.14423/smj.0000000000000329.
Wang SB, Mitchell P, Chiha J, Liew G, Plant AJ, Thiagalingam A, Burlutsky G, Gopinath B. Severity of coronary artery disease is independently associated with the frequency of early age-related macular degeneration. Br J Ophthalmol. 2015;99:365–70. https://doi.org/10.1136/bjophthalmol-2014-305793.
Joachim ND, Mitchell P, Kifley A, Wang JJ. Incidence, progression, and associated risk factors of medium drusen in age-related macular degeneration: findings from the 15-year follow-up of an Australian cohort. JAMA Ophthalmol. 2015;133:698–705. https://doi.org/10.1001/jamaophthalmol.2015.0498.
Orban T, Johnson WM, Dong Z, Maeda T, Maeda A, Sakai T, Tsuneoka H, Mieyal JJ, Palczewski K. Serum levels of lipid metabolites in age-related macular degeneration. FASEB J. 2015;29:4579–88. https://doi.org/10.1096/fj.15-275289.
Li M, Zhang X, Liao N, Ye B, Peng Y, Ji Y, Wen F. Analysis of the serum lipid profile in polypoidal choroidal vasculopathy. Sci Rep. 2016;6:38342. https://doi.org/10.1038/srep38342.
Ersoy L, Ristau T, Lechanteur YT, Hahn M, Hoyng CB, Kirchhof B, den Hollander AI, Fauser S. Nutritional risk factors for age-related macular degeneration. Biomed Res Int. 2014;2014:413150. https://doi.org/10.1155/2014/413150.
Klein R, Myers CE, Buitendijk GH, Rochtchina E, Gao X, de Jong PT, Sivakumaran TA, Burlutsky G, McKean-Cowdin R, Hofman A, Iyengar SK, Lee KE, Stricker BH, Vingerling JR, Mitchell P, Klein BE, Klaver CC, Wang JJ. Lipids, lipid genes, and incident age-related macular degeneration: the three continent age-related macular degeneration consortium. Am J Ophthalmol. 2014;158:513-24.e3. https://doi.org/10.1016/j.ajo.2014.05.027.
Pertl L, Kern S, Weger M, Hausberger S, Trieb M, Gasser-Steiner V, Haas A, Scharnagl H, Heinemann A, Marsche G. High-density lipoprotein function in exudative age-related macular degeneration. PLoS One. 2016;11:e0154397. https://doi.org/10.1371/journal.pone.0154397.
Paun CC, Ersoy L, Schick T, Groenewoud JM, Lechanteur YT, Fauser S, Hoyng CB, de Jong EK, den Hollander AI. Genetic variants and systemic complement activation levels are associated with serum lipoprotein levels in age-related macular degeneration. Investig Ophthalmol Vis Sci. 2015;56:7766–73. https://doi.org/10.1167/iovs.15-17035.
Triebwasser MP, Roberson ED, Yu Y, Schramm EC, Wagner EK, Raychaudhuri S, Seddon JM, Atkinson JP. Rare variants in the functional domains of complement factor H are associated with age-related macular degeneration. Investig Ophthalmol Vis Sci. 2015;56:6873–8. https://doi.org/10.1167/iovs.15-17432.
Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. Complement system part I—molecular mechanisms of activation and regulation. Front Immunol. 2015;6:262. https://doi.org/10.3389/fimmu.2015.00262.
Fleckenstein M, Keenan TDL, Guymer RH, Chakravarthy U, Schmitz-Valckenberg S, Klaver CC, Wong WT, Chew EY. Age-related macular degeneration. Nat Rev Dis Prim. 2021;7:31. https://doi.org/10.1038/s41572-021-00265-2.
Rozing MP, Durhuus JA, Krogh Nielsen M, Subhi Y, Kirkwood TB, Westendorp RG, Sørensen TL. Age-related macular degeneration: a two-level model hypothesis. Prog Retin Eye Res. 2020;76:100825. https://doi.org/10.1016/j.preteyeres.2019.100825.
Yamashiro K, Yanagi Y, Koizumi H, Matsumoto H, Cheung CMG, Gomi F, Iida T, Tsujikawa A. Relationship between pachychoroid and polypoidal choroidal vasculopathy. J Clin Med. 2022;11:4614. https://doi.org/10.3390/jcm11154614.
Holtz JK, Larsson JME, Hansen MS, van Dijk EHC, Subhi Y. Pachychoroid spectrum diseases in patients with Cushing’s syndrome: a systematic review with meta-analyses. J Clin Med. 2022;11:4437. https://doi.org/10.3390/jcm11154437.
Subhi Y, Krogh Nielsen M, Molbech CR, Krüger Falk M, Singh A, Hviid TVF, Nissen MH, Sørensen TL. Association of CD11b+ monocytes and anti-vascular endothelial growth factor injections in treatment of neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. JAMA Ophthalmol. 2019;137:515–22. https://doi.org/10.1001/jamaophthalmol.2019.0010.
Subhi Y, Krogh Nielsen M, Molbech CR, Oishi A, Singh A, Nissen MH, Sørensen TL. Plasma markers of chronic low-grade inflammation in polypoidal choroidal vasculopathy and neovascular age-related macular degeneration. Acta Ophthalmol. 2019;97:99–106. https://doi.org/10.1111/aos.13886.
Subhi Y, Nielsen MK, Molbech CR, Liisborg C, Søndergaard HB, Sellebjerg F, Sørensen TL. The transcriptome of peripheral blood mononuclear cells in patients with clinical subtypes of late age-related macular degeneration. Immun Ageing. 2019;16:20. https://doi.org/10.1186/s12979-019-0160-0.
Subhi Y, Krogh Nielsen M, Molbech CR, Oishi A, Singh A, Nissen MH, Sørensen TL. Polypoidal choroidal vasculopathy associate with diminished regulatory T cells that are polarized into a t helper 2-like phenotype. Investig Ophthalmol Vis Sci. 2019;60:2583–90. https://doi.org/10.1167/iovs.19-26882.
Acknowledgements
Funding
This study was funded by the National Natural Science Foundation of China (grants: 81470649, 81670870); the Science and Technology Innovation Project of Chinese Academy of Medical Sciences (2018-I2M-HL-019); the Beijing Nova Program (Z161100004916058); the Huaxia Translational Medicine Fund for Young Scholars (2017-C-001); and the Xiamen Medical and Health Project (3502Z20189022). The study sponsors also funded the journal’s Rapid Service Fee.
Authorship
All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.
Author Contributions
Concept and design: Lvzhen Huang; methodology: Hui Xu; data collection: Yong Cheng, Xuan Shi, Yaoyao Sun, Mingwei Zhao; statistical analysis: Xiaoyun Ma; drafting the manuscript: Tianchang Tao; preparing tables: Hui Xu; supervision: Xiaoxin Li.
Disclosures
Tianchang Tao, Hui Xu, Xiaoyun Ma, Yong Cheng, Xuan Shi, Yaoyao Sun, Mingwei Zhao, Lvzhen Huang, and Xiaoxin Li declare that they have no competing interests.
Compliance with Ethics Guidelines
This study was approved by the Ethical Committee of Peking University People’s Hospital. All procedures were performed in accordance with the tenets of the Declaration of Helsinki of 1964 and its later amendments. All participants signed informed consent forms before research.
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Tao, T., Xu, H., Ma, X. et al. Analysis of Systemic and Serum Risk Factors in Patients with Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy. Ophthalmol Ther 12, 1033–1044 (2023). https://doi.org/10.1007/s40123-023-00650-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40123-023-00650-y